Patent buyouts risk aggravating certain innovation issues and are unattractive due to upfront costs
Frank Mueller-Langer 2013 Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research? Published online by Cambridge University Press: 24 January 2013 Health Economics, Policy and Law. 2013;8(2):185-208. doi:10.1017/S1744133112000321
Second, patent buyouts could aggravate the problem of patent races and wasteful duplication of R&D expenses, as the price the patent authority would pay for a patent is typically higher than its private (commercial) value (Gallini and Scotchmer, ). Additionally, patent buyouts are a visible lump sum payment and thus are likely to be less politically attractive than the less visible patent revenues spread out over a large number of doses (Maurer, ).